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ferric citrate experienced signiﬁcant increases in serum ferritin (þ10%) and
TSAT (þ18%) after 4 weeks of treatment.
We analyzed electronic medical records of patients with concurrent rises
in TSAT (Z 10%) and ferritin (15% to 25%) between 6/1/08 and 12/31/10,
excluding patients with signiﬁcant change in iron or erythropoiesis-
stimulating agent (ESA) dose, hemoglobin, or change in PB during the prior
month. We assessed changes in epoetin alfa and iron dosing when
physicians observed these increases in lab values. We constructed a cost
offset model from a per patient per month (PPPM) considering average
sales price of epoetin and iron that assumed equivalent phosphorus
outcomes and pricing across all PB.
The analysis included 2,037 concurrent, non-treatment related rises in
ferritin and TSAT. Decreases in dose/dialysis session in mean epoetin and
iron use 2 months following the index date represented an average
combined savings of $90.51 to $181.01 PPPM. The model was most
sensitive to baseline drug doses: patients at highest baseline epoetin doses
(4 9,000U/session) showed savings of $471.80 to $943.61 PPPM.
Based on actual physician behavior in response to ferritin and TSAT
increases and ferric citrate clinical trial results, and assuming equivalent
pricing to other PBs, there would be cost savings with ferric citrate use
through reduced ESA and iron use.
http://dx.doi.org/10.1016/j.krcp.2012.04.414
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EFFECT OF ASCORBIC ACID ON EPO-HYPORESPONSIVE ANEMIA IN
HEMODIALYSIS PATIENTS
Jimin Jeon, Yongki Park
Dong Rae Bong Seng Hospital, Busan, Korea
We performed the present study to evaluate the efﬁcacy of intravenous
and oral ascorbic acid in improving anemia and iron availability on EPO-
hyporesponsive anemia in hemodialysis patients with hyperferritinemia.
This study of three months duration was conducted in 49 patients with Hb
o11 g/dL and ferritin levels greater than 300 ng/ml. Blood samples for
measurement of Hb, Hct, serum iron, ferritin, TIBC, transferrin saturation,
EPO dose were obtained after baseline and at the end of study after three
months. Patients were randomly divided into three groups. 16 patients had
received standard care(group 1), 17 patients had received standard care
and daily oral ascorbic acid at a dose of 500 mg/day(group 2), and 16
patients had received standard care and 300mg of intravenous vitamin C
with each dialysis session(group 3). Forty-seven patients completed the
study. All of patients dialyzed 4 hours, 3 times a week with similar kt/V.
Hb, serum iron, serum ferritin, transferrin saturation and EPO dose was
similar in the three groups at baseline. After 3 month, Hemoglobin and
hematocrit and transferrin saturation signiﬁcantly increased in group 2,3.
but not changed in group 1. EPO dose and ferritin level decreased in group
2,3. but not changed in group 1. There was no difference between group
2 and 3. In conclusion, intravenous or oral ascorbic acid therapy can
improve hyperferritinemia and EPO hyporesponsive anemia in




IMPACT OF RENAL TRANSPLANTATION ON BODY COMPOSITION
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The aim of the study was to analyse the impact of renal transplantation
on body composition (Body Cell Mass) in adult kidney transplant
recipients.Body Cell Mass (BCM) was calculated from total body potassium
(TBK), determined from K-40 in a whole body counter. Patients were
measured before transplantation and 3 months, 1 year and 2 years after
transplantation. Patients were encouraged to take part in physical exercise,
but supervised physical training was not included in the study Out of 50
included patients, 44 have had a kidney transplant (9 F, 35 M). Mean age at
transplantation was 49 (23-72) years. Before transplantation, mean BW
was 80 (SD 13) kg and mean BMI 25,6 (SD 4) kg/m2. Mean TBK was 3162
(SD 690) mmol, corresponding to 90 % of predicted value. In the 1 year
follow up, no signiﬁcant changes in TBK (n¼42) were found, nor in patients
examined 2-3 years after transplantation (n¼35). To examine whether
post transplantation improvement of BCM will appear later, as has been
seen in Liver Transplant recipients, patients were invited to a follow up
measurement. So far, 11 patients have repeated the measurement 6 (4½-
7½) years after transplantation. TBK improvements of 410% were seen in
4 patients, decreases of 410% in 2 patients, and changes of a lower
magnitude in remaining patients. In conclusion, no increase in Body Cell
Mass was seen in this unselected group of kidney transplant recipients
during the ﬁrst 2-3 years after transplantation. Pro catabolic events and
low physical activity may explain this lack oﬁmprovement.
http://dx.doi.org/10.1016/j.krcp.2012.04.416
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Whether excess sodium intake is a risk factor for coronary heart disease
(CHD) has recently been challenged, despite compelling evidence for its
adverse effects on blood pressure and extracellular volume. We examined
the association between sodium intake and risk of CHD in the overall
population and in subgroups potentially more susceptible to the
detrimental effects of high sodium intake.
We included 7779 adults without previous cardiovascular diseases or
cancer at baseline (1997-1998) from the observational, community-based
PREVEND study. Sodium intake was estimated from two 24-h urine
collections and normalized to creatinine excretion. Hypertension and
N-Terminal pro-B-type Natriuretic Peptide (NTproBNP) levels above the
sex-speciﬁc median were deﬁned as predisposing factors to the adverse
effects of high sodium intake. We documented 464 events, during a median
follow-up of 10.5 y, There was some evidence for a trend between sodium
intake and risk of CHD in the entire cohort after adjustment for CHD risk
factors [Hazard ratio (HR), 1.06; 95% conﬁdence interval (CI), 0.97-1.17 per
SD increment]. Each SD increment in sodium intake was associated with a
higher risk for CHD only among subjects with hypertension (n¼2453; HR,
1.14; 95% CI, 1.01-1.29) and with elevated NTproBNP levels (n¼3796; HR,
1.14; 95% CI, 1.02-1.28).
In conclusion, a higher sodium intake was associated with an increased
risk of CHD among subjects with hypertension and elevated levels of
Table 1. Baseline and 3 month Data
Group1(n¼16) Group2(n¼17) Group3(n¼14)
baseline After3month baseline After3month baseline After3month
Hb(g/dl 8.9þ1.4 8.8þ1.3 8.8þ1.3 9.5þ1.2 9.0þ1.2 9.6þ1.2
Fe(u/L) 55.84þ23 58.6þ19 58.57þ25 63.7þ22 61.12þ21 6729þ19
EPOdose(unit/week)14729 14538 15584 12369 14986 11345
Ferritin(ug/l) 764þ217 781þ192 783þ191 646þ189 754þ220 634þ231
Transferrin
saturation(%)
18þ6.4 18þ5.8 20.6þ5.5 26.4þ4.4 19.8þ4.9 24.5þ3.2
*is po0.5
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NTproBNP. These individuals might be vulnerable to the deleterious impact
of high sodium intake on CHD risk.
per SD increment in sodium-creatine ratio
0.7 0.8 0.9 1.0 1.1 1.2 1.3
     >Sex-specific median
≤Sex-specific median
NT-proBNP
     Yes
     No
Hypertension
Adjusted HR (95% CI)
http://dx.doi.org/10.1016/j.krcp.2012.04.417
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Magnesium has been favorable associated with many cardiovascular
(CVD) risk factors. Previous studies on dietary magnesium and risk of CVD
have yielded inconsistent results, possibly due to the use of dietary
questionnaires or blood levels to assess magnesium exposure. Whether
urinary excretion of magnesium, as reﬂection of actual dietary uptake, is
associated with CVD risk remains unclear.
We prospectively followed 7747 adults free of diagnosed cardiovascular
diseases or cancer at baseline (1997-1998) from the community-based,
observational PREVEND (Prevention of Renal and Vascular End-Stage
Disease) Study. Urinary magnesium excretion was estimated from two 24-
h urine collections and was measured by a xylidyl blue method on a
Modular analyzer (Roche). During a median follow-up of 10.5 year, 638
CVD events occurred. After adjustment for age, BMI, sex, smoking status,
alcohol consumption and educational attainment, urinary magnesium
excretion showed a nonlinear relationship with CVD risk. The hazard ratios
(HR) for CVD were signiﬁcantly lower (Po0.05) among the highest four
quintiles compared with the lowest sex-speciﬁc quintile (men: o2.56
mmol/24h; women: o2.09 mmol/24h). The lowest sex-speciﬁc quintile
had an increased risk of CVD (HR, 1.53; 95% conﬁdence interval (CI), 1.26-
1.84) compared with the rest of the cohort after adjustment for
confounders and urinary cations. Further adjustment for C-reactive protein,
systolic blood pressure, total to HDL cholesterol ratio and type 2 diabetes,
did not appreciably alter this association (HR, 1.44; 95% CI, 1.18-1.75).
>In conclusion, low urinary magnesium excretion was associated with a
higher risk of CVD, even after controlling for possible intermediates in the
causal pathway such as blood pressure, diabetes and markers of
inﬂammation and atherosclerosis. These results highlight the need to
evaluate whether increasing the uptake of dietary magnesium could be
effective for primary prevention of CVD.
http://dx.doi.org/10.1016/j.krcp.2012.04.418
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Junichi Hoshino, Miklos Z Molnar, Kamyar Kalantar-Zadeh
Harbor-UCLA Medical Center, Torrance, California
HbA1c has been widely used as a clinically important assessment tool for
outcome analyses related to glycemic control. However, there is no HbA1c-
blood glucose equation formula speciﬁc for hemodialysis (HD) patients. In
this study, we sought to develop HbA1c-blool glucose equation models for
dialysis patients. We examined associations between HbA1c levels and
random serum glucose levels over time in a contemporary cohort of 18,361
diabetic maintenance HD patients treated in DaVita dialysis clinics from
July 2001 through June 2006 with 276,277 paired measurements of HbA1c
and glucose. Time-averaged HbA1c values and blood glucose (BG) values
were compared using regression models with and without adjustment for
hemoglobin, albumin, patients’ age, gender, and/or race/ethnicity to
determine a new equation model. The new models were compared to the
previously reported equations (DCCT and ADAG).
modal formula adjust R2
Our modal BG¼53.7þ28.8*HbA1c-18.2*Alb 0.3243
DCCT BG¼35.6*HbA1c-77.3 0.3141
ADAG BG¼28.7*HbA1c-46.7 0.3141
In conclusion, the association between HbA1c and BG in HD patients is
different from non-HD patient. Our proposed model results in better
estimated BG level in HD patients compared to previously reported models.
http://dx.doi.org/10.1016/j.krcp.2012.04.419
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Serum albumin is one of the strongest mortality-predictors in MHD
patients. Yet, the degree to which serum albumin represents dietary
protein intake or inﬂammation is not clear. We hypothesized that
inadequate protein intake and inﬂammation contribute equally to
hypoalbuminemia and examined correlates of low serum albumin o3.8 g/
dL in 812 MHD patients in whom interleukin-6 (IL-6) and normalized
protein nitrogen appearance (nPNA), also known as normalized protein
catabolic rate (nPCR), were also measured. Logistic regression estimated
odds ratios were employed and spline models were plotted to examine the
likelihood of low serum albumin o3.8 g/dL. Mean age (7SD) of patients
was 54715 years; 53% of patients were men, 50% Hispanic, 31% African-
American and 55% diabetic. The unadjusted correlation coefﬁcients of IL-6
and nPNA with serum albumin were -0.36 and þ0.20, respectively
(po0.001 for each comparison). The likelihood for an albumin o3.8 gr/dL
increased linearly with decreasing nPNA and rising serum IL-6. This trend
was steeper with increasing serum IL-6 up to a concentration of 30 ng/ml
(Figure). Hence, both low protein intakes and a high state of inﬂammation
are associated with low serum albumin in MHD patients.
http://dx.doi.org/10.1016/j.krcp.2012.04.420
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